Pamela is an experienced regulatory affairs professional with 14 years of industry experience in global regulatory Chemistry, Manufacturing and Controls (CMC) as well as analytical development. She implements regulatory strategies and risk assessments for Aceragen product development teams from pre-IND to post-approval.
Prior to joining Aceragen, Pamela has worked directly on approved drug products in the market such as Telaprevir, Kevzara and Dupixent. She’s served in positions of increasing CMC-related responsibility in several pharmaceutical companies. She holds a Ph.D. in analytical chemistry from the University of Florida.
